Prediction of post-vaccination Guillain-Barré syndrome using data from a passive surveillance system

Chongliang Luo1 | Ying Jiang2 | Jingcheng Du3 | Jiayi Tong1 | Jing Huang1 | Vincent Lo Re III1 | Susan S. Ellenberg1 | Gregory A. Poland4 | Cui Tao3 | Yong Chen1

1Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, Pennsylvania, USA
2Department of Neurology and Multiple Sclerosis Research Center, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
3School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, Texas, USA
4Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, Minnesota, USA

Correspondence
Yong Chen, Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, PA 19104, USA.
Email: ychen123@upenn.edu

Cui Tao, School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA.
Email: cui.tao@uth.tmc.edu

Abstract

Purpose: Severe adverse events (AEs), such as Guillain-Barré syndrome (GBS) occur rarely after influenza vaccination. We identify highly associated AEs with GBS and develop prediction models for GBS using the US Vaccine Adverse Event Reporting System (VAERS) reports following trivalent influenza vaccination (FLU3).

Methods: This study analyzed 80,059 reports from the US VAERS between 1990 and 2017. Several AEs were identified as highly associated with GBS and were used to develop the prediction model. Some common and mild AEs that were suspected to be underreported when GBS occurred simultaneously were removed from the final model. The analyses were validated using European influenza vaccine AEs data from EudraVigilance.

Results: Of the 80,059 reports, 1,185 (1.5%) were annotated as GBS related. Twenty-four AEs were identified as having strong association with GBS. The full prediction model, using age, sex, and all 24 AEs achieved an area under the receiver operating characteristic (ROC) curve (AUC) of 85.4% (90% CI: [83.8%, 86.9%]). After excluding the nine (e.g., pruritus, rash, injection site pain) likely underreported AEs, the final AUC became 77.5% (90% CI: [75.5%, 79.6%]). Two hundred and one (0.25%) reports were predicted as of high risk of GBS (predicted probability >25%) and 84 actually developed GBS.

Conclusion: The prediction performance demonstrated the potential of developing risk-prediction models utilizing the VAERS cohort. Excluding the likely underreported AEs sacrificed some prediction power but made the model more interpretable and feasible. The high absolute risk of even a small number of AE combinations suggests the promise of GBS prediction within the VAERS dataset.

KEYWORDS
Guillain-Barré syndrome, risk prediction model, trivalent influenza vaccine, underreporting, vaccine pharmacovigilance, VAERS

1 | INTRODUCTION

Vaccination is one of the most effective methods of protecting the general population from dangerous infectious illnesses. Due to
vaccines, many diseases such as diphtheria, tetanus, Haemophilus influenzae type b (Hib) disease, poliomyelitis, measles, mumps, congenital rubella, and smallpox have been dramatically reduced or even eradicated worldwide. Vaccines, like other biological products can also cause various side effects. As vaccines are usually administrated to healthy persons, adverse events (AEs) after vaccination may arouse suspicion about the safety of the vaccines and cause vaccine hesitancy or refusal in certain populations. Post-marketing surveillance is needed in the general population in order to identify and evaluate AEs for vaccine safety studies.

The Vaccine Adverse Event Reporting System (VAERS) was established by the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) to collect reports about AEs after vaccination. Since its creation in 1990, VAERS has been used to continually monitor reports following vaccination to determine whether a vaccine has a higher than expected rate of AEs, especially for those rare AEs that are difficult to evaluate in clinical trials during the vaccine development stage. Rare AEs of certain vaccines (i.e., safety signals) are commonly detected by disproportionality analysis, which compares their rates with certain background rates. These statistically significant signals offer hypotheses that can be further studied to assess causality.

Due to the well-known limitations of the spontaneous reporting data, the use of VAERS data for risk prediction has been limited. VAERS is also subject to reporting bias, such as underreporting of AEs, especially for common and mild events. In addition, there is no control group or validation data that would allow a generalizable conclusion. As a result, any predictive model should be conducted and interpreted with caution. There is limited research on risk prediction using VAERS. One such study is by Pellegrino et al., who systematically reviewed the pharmacogenetic studies related to VAERS and provided recognized genetic risk factors. In the era of big data, machine-learning techniques and data-driven methods are being increasingly applied to medical and healthcare areas and have achieved important successes. In the context of vaccine pharmacovigilance, an applicable risk-prediction model makes early intervention possible, which could prevent or mitigate some severe AEs.

In this study, we studied the occurrence of Guillain-Barré syndrome (GBS) after influenza vaccination. GBS, an acute immune-mediated peripheral neuropathy, is suspected as one of the most common acute paralytic neuromuscular disorders and one of the most severe AEs following immunization (AEFIs) in adults. The occurrence of GBS among the general population is rare, and estimates of incidence range from 0.8 to 1.9 cases per 100 000 person-years. Influenza vaccines have long been suspected to increase the risk of GBS. Some studies have found associations between influenza vaccination and GBS, while other studies have not, and the association between seasonal influenza vaccine and GBS can vary from season-to-season. Thus, there remains doubt over the causative nature of the influenza vaccines with GBS.

Despite the effort devoted to studying the association between the risk of GBS and influenza vaccination, it is important for the public to know that getting seasonal influenza vaccines is the best way to prevent flu infection and complications. Meanwhile, potential risk prediction for GBS onset is also critical as it may provide early alerts to the rare population who might at the risk of getting GBS. Little research has been conducted to identify the AEs that are related to GBS among post-vaccination subjects, which can be used to develop risk-prediction models. It is difficult to accurately diagnose GBS at an early stage due to its diverse causes and clinical presentations; however, those patients with a high risk of contracting GBS following influenza vaccination identified by our model could be more alert to the fluctuation of symptoms and seek medical treatment before the possible onset of GBS. The purpose of our investigation is to identify novel risk factors and generate a novel risk prediction model, which needs to be further validated by prospective studies. Once validated, the risk prediction models could lead to useful insights for clinical decision making.

### Data processing and cohort characteristics

At the end of 2018, the VAERS database contained more than 400 000 vaccine-associated AE reports. Each report had been manually annotated at the preferred-term (PT) level in the Medical
Dictionary for Regulatory Activities (MedDRA) by domain experts. According to the CDC, the VAERS reports had been screened to remove duplicate reports.\textsuperscript{20} We extracted all of the VAERS reports submitted after FLU3 vaccination from 1990 to 2017. The detailed flow chart of the data processing and the analysis procedure was in Figure 1. VAERS reports typically include more than one AE, with the median number of AEs being 3, and 20\% of reports contains only one AE. After quality control (e.g., exclusion of reports with age < 0.5 or missing age or sex, removal of AEs due to the investigation related MedDRA terms), we obtained 80,059 reports and 2,977 unique AEs other than GBS. The total number of GBS-related reports was 1,185. Cohort characteristics, such as age, sex, and onset interval distribution were displayed in Table 1. Additionally, we also processed the European EudraVigilance data and used them for validation purpose. The European data were obtained from European Medicines Agency (EMA) at 2016 and included influenza vaccines AE reports from 2003 to 2016. We filtered out the reports where the occurrence was outside European area. 13,550 reports were extracted, of which 327 reports were GBS-related. Due to data access limitation, the European data contained all the influenza vaccines.

### 2.2 Association analysis and AE screening

We constructed a 2-by-2 table for each AE and measured its association with GBS by the odds ratio (OR) and tested the significance by Chi-squared test. To enhance the reproducibility of our findings, we applied a conservative Bonferroni correction for multiple testing, with the overall nominal significance level $\alpha = 0.05$.

We screened the identified AEs for clinical interpretation and further risk prediction. We first screened out extremely rare AEs with a prevalence of less than 0.05\%. After consultation with a neurologist, we also screened out those AEs that are actually typical of GBS treatments (as MedDRA also contains medical and health-related concepts beyond AEs), very severe and typical GBS symptoms, or known to happen after GBS treatment. The identified AEs were validated using the European data by comparing their prevalence and ORs in both data sets.

### 2.3 Risk-prediction model

We built logistic regression models to predict the occurrence of GBS after FLU3 vaccination, using age, sex and associated AEs. All models were fit using the same set of training data (80\% of all cohorts), and performance was measured by the AUC\textsuperscript{21} value of predicting the same set of testing data (20\% of all cohorts). The first naive model, which included only age and sex, was presented for baseline comparison. The second model was fit using age, sex, and the identified AEs. The second model may be questionable, as it involves the negatively associated AEs which are more likely to be underreported when GBS occurs and as a result, the association may be distorted. To obtain an applicable predictive model, we further excluded this group of AEs and used only the positively associated AEs, as well as sex and age, to build the final model. The absolute risk of each factor and the AE combinations were also presented by refitting the final model using the full US data. Similar prediction was also conducted in the European data, using the same set of predictors as in the US data.

### 3 RESULTS

#### 3.1 Descriptive analysis

The population characteristics in the extracted reports were summarized in Table 1. Age was categorized into four groups: 0.5–17, 18–49, 50–64, and 65+ years. For the US population, the median age was 50 years, with the interquartile range (IQR) from 29 to 66. Nearly
70% of the cohort was female. Most reports that were not related to GBS had an onset time within 1 week, whereas more than 70% of the reports that were GBS related had an onset time that exceeds 1 week.

| Variable                        | GBS related (%) | Not GBS related (%) |
|---------------------------------|-----------------|---------------------|
| **US FLU3, 1990–2017**         |                 |                     |
| Total                           | 1185 (100)      | 78 874 (100)        |
| Female                          | 563 (47.5)      | 55 257 (70.1)       |
| Age of male, median (IQR)       | 60 (46–69)      | 46 (11–66)          |
| 0.5–17                          | 29 (4.7)        | 6956 (29.5)         |
| 18–49                           | 150 (21.4)      | 5749 (24.3)         |
| 50–64                           | 206 (33.1)      | 4221 (17.9)         |
| 65+                             | 237 (38.1)      | 6691 (28.3)         |
| Age of female, median (IQR)     | 56 (40.5–67)    | 51 (33–66)          |
| 0.5–17                          | 33 (5.9)        | 6461 (11.7)         |
| 18–49                           | 177 (31.4)      | 19 590 (24.3)       |
| 50–64                           | 184 (32.7)      | 13 050 (23.6)       |
| 65+                             | 169 (30)        | 16 156 (29.2)       |
| Onset interval of male (week)   |                 |                     |
| 1                               | 143 (23)        | 19 724 (83.5)       |
| 2                               | 166 (26.7)      | 937 (4)             |
| 3–4                             | 133 (21.4)      | 429 (1.8)           |
| 5+                              | 153 (24.6)      | 596 (2.5)           |
| NA                              | 27 (4.3)        | 1931 (8.2)          |
| Onset interval of female (week) |                 |                     |
| 1                               | 174 (30.9)      | 48 709 (88.1)       |
| 2                               | 131 (23.3)      | 1311 (2.4)          |
| 3–4                             | 101 (17.9)      | 661 (1.2)           |
| 5+                              | 122 (21.7)      | 891 (1.6)           |
| NA                              | 35 (6.2)        | 3685 (6.7)          |
| **European all FLU, 2003–2016** |                 |                     |
| Total                           | 327 (100)       | 13 223 (100)        |
| Female                          | 136 (41.6)      | 7874 (59.5)         |
| Age of male, median (IQR)       | 62 (52–73)      | 47 (15–66)          |
| 0.5–17                          | 5 (2.6)         | 1518 (28.4)         |
| 18–49                           | 34 (17.8)       | 1292 (24.2)         |
| 50–64                           | 68 (35.6)       | 1041 (19.5)         |
| 65+                             | 84 (44)         | 1498 (28)           |
| Age of female, median (IQR)     | 61 (48–72)      | 46 (27–64)          |
| 0.5–17                          | 2 (1.5)         | 1315 (16.7)         |
| 18–49                           | 37 (27.2)       | 2999 (38.1)         |
| 50–64                           | 42 (30.9)       | 1685 (21.4)         |
| 65+                             | 55 (40.4)       | 1875 (23.8)         |

This was consistent with results from Haber et al.\textsuperscript{22} To show how multiple AEs were temporally ordered in one report, we manually reviewed and annotated 15 US reports and presented them in Figure S1 of the supporting information. The first six reports ended with GBS as the last reported event. Compared to non-GBS reports, GBS tends to occur later than non-GBS AEs, consistent with the pathophysiology of GBS. Most of the AEs were very rare. For example, 90% of the AEs were reported fewer than 90 times throughout the 28 year timeframe we examined.
FIGURE 2  A, ROC of GBS prediction in US VAERS FLU3, using logistic regression models. The full model uses age, sex, and the 24 AEs (in blue); the naïve model uses only age and sex (in red); and the final model uses age, sex, and the 15 AEs, excluding the nine AEs that are suspicious of underreporting (in green). B, Predicted absolute risk of all single AE and 2-AE combinations. If the combination is not observed in the cohort, it is imputed by the fitted regression model with age, sex, and 15 associated AEs. C, Predicted absolute risk versus number of AEs [Colour figure can be viewed at wileyonlinelibrary.com]
3.2 | Association analysis and AE screening

We identified 83 AEs from the US data, among which 24 were kept after further screened by clinical experts. The detail of the screening procedure was deferred to the supporting information. The identified AEs and the validation using the European data were listed in Table 2.

We evaluated the identified AEs in terms of their association with GBS and prevalence among the VAERS FLU3 cohort. Nine AEs (pyrexia, chills, nausea, pruritus, rash, urticaria, injection site pain, injection site swelling and injection site erythema) were negatively associated with GBS, and their prevalence was high. Thirteen AEs (muscle spasms, hypertension, dysphagia, hyperglycaemia, diabetes mellitus, dysuria, depression, apnea, fecal incontinence, constipation, urinary incontinence, dysuria, urinary tract infection and urinary retention) were positively associated with GBS, but their prevalence was low (<1%). Back pain and paraesthesia were two AEs that were both positively associated with GBS and have a relatively high prevalence. Interestingly, the associations and prevalence of these AEs in the US data are highly consistent with those in the European data. Specifically, the same nine AEs were also negatively associated with GBS and have relatively high prevalence in the European data. The remaining 15 AEs were also positively associated with GBS in the European data.

As noted above, the nine AEs that are negatively related to GBS are more common and mild and thus more likely to be underreported, especially when a severe AE such as GBS occurs. This underreporting could alter the direction of their association with GBS and make the prediction not applicable. In contrast, for the other 15 AEs that are less common and mild, the bias is expected to be relatively small.

3.3 | Predictive modeling

Figure 2A shows the ROC curves of GBS prediction using three nested models with different predictors in the US data. As a benchmark, the naïve model that contains only age and sex results in an AUC of 68.5% (90% CI: [65.7%, 71.2%]). The full model using age, sex, and all 24 AEs, including the possibly underreported 9 AEs, achieves an AUC of 85.4% (90% CI: [83.8%, 86.9%]). The final model, which excludes the possibly underreported nine AEs, achieves an AUC of 77.5% (90% CI: [75.5%, 79.6%]). As an independent validation, the values of AUC are 69.7% (90% CI: [66.0%, 74.4%]), 78.5% (90% CI: [74.9%, 83.7%]), and 75.7% (90% CI: [71.7%, 81.1%]) respectively for the naïve model, the full model and the final model in the European data.

The final model was fit again using all of the US data, and the risk ratios are listed in Table S1. Paraesthesia (OR = 9.93, 95% CI = 8.60–11.46) and apnea (OR = 11.72, 95% CI = 6.88–19.94) are high-risk factors for GBS. Age (49–64) and sex (male) are also high-risk factors for GBS. The predicted absolute risk is presented in Figure 2B,C. The absolute risk of all single AEs and combinations of two AEs are plotted in Figure 2B. Even for only two AEs together, the absolute risk can be as high as 30% and above. For example, the combination of apnea and paraesthesia has a predictive risk of 66%. This combination consists of seven subjects, of which four report GBS. Since usually only a few of the identified AEs are reported, this combination table can be used as a quick reference tool for identifying the risk of GBS when certain AEs are observed. We plot the absolute risk versus the number of AEs in Figure 2C, where 201 (0.25%) reports were predicted as of high risk of GBS (e.g., risk > 25%) and 84 actually developed GBS, the PPV is thus 41.8%.

4 | DISCUSSION

Vaccination is one of the most successful public health interventions ever implemented. It is important to study vaccine safety issues in order to maintain high levels of public trust in vaccines, and thereby mitigate vaccine hesitation. In this paper, we developed a risk-prediction model for GBS using associated AEs identified from VAERS data. To the best of our knowledge, this approach is the first attempt to utilize VAERS data for risk prediction. We demonstrate the potential to develop a GBS “alarm signal” based solely on reported VAERS AEs. The application of the prediction model can be valuable for persons receiving a FLU3 vaccination, for clinicians as a means to understand the likelihood of developing GBS, for regulators or companies to detect a signal of GBS early in the use of a vaccine, and for scientists who seek to understand mechanisms for GBS.

The purpose of this study was to determine whether certain AEs are associated with GBS, rather than the association of GBS with influenza vaccination. Our study thus differed from existing signal detection studies that use VAERS data, as our investigation focused on the study population captured by VAERS rather than the entire vaccinated population. The identified signals were validated by an independent European vaccine self-reporting system data, where all the identified AEs had the same directions of associations with GBS, compared to the identified associations in the US data. We demonstrated the feasibility of using early AEs for the prediction of GBS, and the risk-prediction models achieved an AUC improvement of 16.9% by including the 24 AEs, or 9.0% by including the 15 AEs, compared to a naïve prediction model with age and sex only. With the cutoff probability at 25%, the final model including the 15 AEs predicted 201 reports as of high risk of GBS, and 84 actually developed GBS. Considering the rareness of GBS reported after vaccination, the positive predicted value (41.8%) is good. It is worth noting that the possible underreporting of these excluded nine AEs was observed in both the US and the European data. We believe excluding them avoids the use of AEs with unknown association to GBS and makes the risk-prediction more interpretable and feasible.

The data-driven association analysis identifies AEs that can motivate further etiology studies, after excluding those AEs with established GBS causality. The nine AEs that are negatively associated with GBS are of the highest prevalence. They are mild and more likely to occur shortly after vaccination. A possible explanation is that either they are protective for GBS or they are subject to underreporting, especially when GBS happens. Although the underreporting pattern is likely the case, we cannot rule out the possibility of a protective effect. On the other hand, some of the 15 identified AEs that are positively associated
with GBS, have been reported to be related to GBS during its early stage in the literature. For example, paraesthesia may be an initial presenting symptom, and bilateral facial weakness with paraesthesias is typically involved in GBS. In addition, autonomic dysfunction, including hypertension and urinary retention, can be a presenting sign of GBS in children, and urinary incontinence should be included in prognostic models for GBS. Some of the identified AEs are likely to be pre-existing conditions, which are also useful for predicting GBS. For example, Kaplan et al. suggest that diabetes mellitus exacerbates the clinical and electrophysiological features of GBS and influences long-term disability. Besides, it's well known that the depression, hyperglycaemia and diabetes mellitus may also relate to immunological abnormality.

The findings from our investigation have potential to impact clinical practices. For example, early treatment of GBS is critical in preventing severe outcomes, such as quadriplegia and respiratory failure. The signals identified by our investigation warrants further independent investigations by other investigators. Once validated, these findings could potentially lead clinicians to advise influenza vaccines to be on the look-out for paraesthesias and apnea, for instance. In addition, these findings might be useful in more accurately pinpointing the timing of onset of symptoms in vaccine safety studies, which is important in determining whether an association with vaccination exists. If some of the associated AEs are true symptoms of a case of GBS-in-development, then clinician-adjudicators of GBS cases in vaccine safety studies could use those symptoms to more accurately determine the timing of GBS symptom onset instead of using limb weakness, which might develop later. From biomedical informatics point of view, the proposed prediction model, after further validation and evaluation, could be implemented in the VAERS system in order to alert for high risk patients with potential severe AEs that have not yet occur. Though we do not have the temporal information of the AEs in VAERS, the prediction based on the identified AEs are still useful, as many of the AEs either happen likely soon after Flu3 vaccination, or are preexisting conditions (e.g., diabetes mellitus).

There are some limitations of our investigation. As spontaneous reporting systems, VAERS, as well as the European EudraVigilance system, both accept reports submitted without validation. Reporting varies over time and is subject to population shift and possible publicity stimulation. In VAERS, the number of annual reports shows a clear increasing trend from the 1990s, with a peak in 2010. This is possibly due to the broader public awareness of vaccine safety and the acceptance of VAERS, or it could be connected to the flu pandemic from early 2009 to 2010. Regarding GBS occurrence within VAERS after FLU3 vaccination, the prevalence of GBS in earlier years (e.g., 1990s) is relatively high (~5%) and become steadily lower in the 2010s (~1%). This could be another example of reporting bias: compared to earlier years, people are more willing to report non-severe AEs due to greater awareness and accessibility of VAERS online submission. In addition, as many AEs are sparse in the annual data, we chose to use data across all years in the association analysis and predictive models. As a result, the approach assumed there was no temporal trend of the association. Another result of the low prevalence of GBS reports (1.5%) is, due to the trade-off between sensitivity and PPV, it is difficult to reach good values of both of them. In our prediction, we set the predicted probability of GBS above 25% as high risk, this results in a PPV of 41.8% (84/201), but a low sensitivity of 7.1% (84/1185). If we use cut-off 10% for high risk, the PPV is 19.6% (250/1274) and the sensitivity is 21.1% (250/1185).

A key issue in risk prediction is the temporal order between the predictor AEs and the outcome GBS, that is, the AEs need to happen before GBS to be valid for prediction. However, manual chart review and annotation for temporal information using VAERS reports at large scale are challenging as most temporal information related to GBS progression are stored in unstructured narrative symptom texts. Based on our investigation of a small subset of reports through manual chart review (see Figure S1 in the supporting information), as well as the literature, the onset time of GBS is likely to be later than the AEs we identified as predictors. In addition, the screening criteria we used, i.e. screening out those typical GBS treatments and those severe and typical GBS-caused symptoms partially alleviate the concerns on the lack of temporal information in the data. Finally, the prediction model is only valid within the VAERS FLU3 cohort (or other spontaneous reporting system such as EudraVigilance), and cannot be directly generalized outside this population.

Our results provide many directions for future research. Similar analysis can be conducted for the VAERS FLU4 population and it would be of interest to investigate the difference between the two major influenza vaccines in use, and the risk of GBS. To generalize the approach to the general population or other vaccine monitoring systems, data integration of multiple sources of pharmacovigilance data is required. For example, this investigation can be further validated and evaluated by other data sources, such as the Vaccine Safety Datalink (VSD), or the active surveillance system SENTINEL. Further studies that use temporal information and more sophisticated methods are needed. A customized natural language processing technique (e.g., CLAMP) could be used to extract the exact onset time information for each individual AE (assuming such information is included in the VAERS reports) in order to develop a more reliable model. Such research is important to further develop risk-based predictive models of important vaccine-associated AEs.

**ETHICS STATEMENT**

Because this study did not involve human subjects it was outside of the purview of institutional review boards.

**CONFLICT OF INTEREST**

Dr. Poland is the chair of a Safety Evaluation Committee for novel investigational vaccine trials being conducted by Merck Research Laboratories. Dr. Poland offers consultative advice on vaccine development to Merck & Co., Medicago, GlaxoSmithKline, Sanofi Pasteur, Emergent Biosolutions, Dynavax, Genentech, Eli Lilly and Company, Janssen Global Services LLC, Kentucky Bioprocessing, and Genevant Sciences, Inc. Dr. Poland holds patents related to vaccinia, influenza, and measles peptide vaccines. Dr. Poland has received grant funding from ICW Ventures for preclinical studies on a peptide-based COVID-19 vaccine. These activities have been reviewed by the Mayo Clinic...
REFERENCES

1. Chen RT, Rastogi SC, Mullen JR, et al. The vaccine adverse event reporting system (VAERS). Vaccine. 1994;12:542-550.
2. Dales L, Hammer SJ, Smith NJ. Time trends in autism and in MMR immunization coverage in California. JAMA. 2001;285:1183-1185.
3. Gilkey MB, Calo WA, Marcinkiew NT, Brewer NT. Parents who refuse or delay HPV vaccine: differences in vaccination behavior, beliefs, and clinical communication preferences. Hum Vaccines Immunother. 2017;13:680-686.
4. Centers for Disease Control and Prevention; Food and Drug Administration. VAERS User Guide. 2020. https://vaers.hhs.gov/docs/VAERSDataUseGuide_October2017.pdf. Accessed February 11, 2021.
5. Zanardi LR, Haber P, Mootrey GT, Niu MT, Wharton M, The VAERS Working Group. Intussusception among recipients of rotavirus vaccine: reports to the vaccine adverse event reporting system. Pediatr. 2004;107(6):e97.
6. Shimabukuro TT, Nguyen M, Martin D, DeStefano F. Safety monitoring in the vaccine adverse event reporting system (VAERS). Vaccine. 2015;33:4398-4405.
7. Pellegrino P, Falvela FS, Perrone V, et al. The first steps towards the era of personalised vaccinology: predicting adverse reactions. Phamacogenomics J. 2015;15(3):284-287.
8. Norgeot B, Glicksberg BS, Butte AJ. A call for deep-learning health care. Nat Med. 2019;25(1):14-15.
9. Coudray N, Ocampo PS, Sakellariopoulos T, et al. Classification and mutation prediction from non-small cell lung cancer histopathology images using deep learning. Nat Med. 2018;24(10):1559-1567.
10. Geier MR, Geier DA, Zahalsky AC. Influenza vaccination and Guillain Barre syndrome. Clin Immunol. 2003;107:116-121.
11. Vellozzi C, Burwen DR, Dobardzic A, Ball R, Walton K, Haber P. Safety of trivalent inactivated influenza vaccines in adults: background for pandemic influenza vaccine safety monitoring. Vaccine. 2009;27:2114-2120.
12. Sejvar JJ, Baughman AL, Wise M, Morgan OW. Population incidence of Guillain-Barré syndrome: a systematic review and meta-analysis. Neuroepidemiology. 2011;36(2):123-133.
13. Lasky T, Terracciano GJ, Magder L, et al. The Guillain-Barre syndrome and the 1992-1993 and 1993-1994 influenza vaccines. N Engl J Med. 1998;339(25):1797-1802.
14. Salmon DA, Proshcan M, Forshee R, et al. Association between Guillain-Barré syndrome and influenza A (H1N1) 2009 monovalent inactivated vaccines in the USA: a meta-analysis. Lancet. 2013;381(9876):1461-1468.
15. Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, et al. Guillain-Barré syndrome following vaccination in the national influenza immunization program, United States, 1976–1977. Am J Epidemiol. 1979;110(2):105-123.
16. Kaplan JE, Katona P, Hurwitz ES, Schonberger LB. Guillain-Barré syndrome in the United States, 1979-1980 and 1980-1981: lack of an association with influenza vaccination. J Am Med Assoc. 1982;248(6):698-700.
17. Stowe J, Andrews N, Wise L, Miller E. Investigation of the temporal association of Guillain-Barré syndrome with influenza vaccine and influenzalike illness using the United Kingdom general practice research database. Am J Epidemiol. 2009;169(3):382-388.
18. Arya DP, Said MA, Izurieta HS, et al. Surveillance for Guillain-Barré syndrome after 2015–2016 and 2016–2017 influenza vaccination of Medicare beneficiaries. Vaccine. 2019;37(43):6543-6549.
19. Centers for Disease Control and Prevention. Vaccine Safety Concerns: Guillain-Barré Syndrome. 2020; https://www.cdc.gov/vaccinesafety/concerns/guillain-barre-syndrome.html. Accessed February 11, 2021.
20. Centers for Disease Control and Prevention. Vaccine Adverse Event Reporting System (VAERS) Fact Sheet. https://www.cdc.gov/vaccinesafety/pdf/vaers_factsheet1.pdf. Accessed February 11, 2021.
21. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;142(1):29-36.
22. Haber P, DeStefano F, Angulo FJ, et al. Guillain-Barré syndrome following influenza vaccination. JAMA. 2004;292(20):2478-2481.
23. Cai Y, Du J, Huang J, et al. A signal detection method for temporal variation of adverse effect with vaccine adverse event reporting system data. BMC Med Inform Decis Mak. 2017;17(2):76.
24. Wakerley BR, Yukl N. Mimics and chameleons in Guillain-Barré and Miller Fisher syndromes. Pract Neurol. 2015;15(2):90-99.
25. Labovitz AE, Margunten HH. Guillain-Barré syndrome presenting with urinary retention and hypertension. Clin Pediatr (Phila). 2004;43(7):659-661.
26. Chen RT, Glasser JW, Rhodes PH, et al. Vaccine Safety Datalink project: a new tool for improving vaccine safety monitoring in the United States. The Vaccine Safety Datalink Team. Pediatr. 1997;99(6):765-773.
27. Soysal E, Wang J, Jiang M, et al. CLAMP—a toolkit for efficiently building customized clinical natural language processing pipelines. J Am Med Informatics Assoc. 2018;25(3):331-336.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of this article.

How to cite this article: Luo C, Jiang Y, Du J, et al. Prediction of post-vaccination Guillain-Barré syndrome using data from a passive surveillance system. Pharmacoepidemiol Drug Saf. 2021;30:602–609. https://doi.org/10.1002/pds.5196